# US 2026/0159838 A1 · Anti-cancer tgfb2 agents with immunotherapeutics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0159838 A1
- Document ID: US20260159838A1
- Status: Published application
- Kind: A1
- Application number: 19/403,110
- Filed: 2025-11-27
- Published: 2026-06-11
- Earliest claimed: 2023-06-05
- Assignees: Gmp Biotechnology Limited
- Applicants: Gmp Biotechnology Limited
- Inventors: Vuong TRIEU
- Web page: https://patentgrep.com/patent/US20260159838A1

## CPC

- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A61K 38/2013: {IL-2}
- A61K 38/202: {IL-3}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/02: Inorganic compounds
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 39/39541: {against normal tissues, cells}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2320/31: Combination therapy
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

This invention relates to methods for treating or ameliorating the symptoms of cancer in a human or animal subject with pharmaceutical compositions designed to promote anti-tumor effects. Exemplary synergistic pharmaceutical therapies include compositions having a combination of active agents including agents for inhibiting or suppressing expression of TGF-β2, immune checkpoint inhibitor agents, and interleukin immunotherapeutic active agents. One or more biomarkers can be used to select subjects who benefit from the method.

## Claims

### Claim 1

A method for treating or ameliorating the symptoms of cancer in a subject in need, the method comprising:
administering a composition comprising an agent for suppressing expression of TGF-β2;
administering an immune checkpoint inhibitor; and
administering an interleukin immunotherapeutic agent to the subject.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein the cancer is a solid cancer, a pancreatic cancer, melanoma, lung cancer, breast cancer, multiple myeloma, or colorectal cancer.

### Claim 5 (depends on 1)

The method of claim 1, wherein the agent for suppressing expression of TGF-β2, the immune checkpoint inhibitor, and the interleukin immunotherapeutic active agent are administered concurrently, simultaneously, sequentially, or separately in time.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition, inhibitor and interleukin immunotherapeutic agent are administered by infusion or injection.

### Claim 7 (depends on 1)

The method of claim 1, wherein the agent for suppressing expression of TGF-β2 is selected from Table 1 or Table 2, and chemically-modified variants thereof, LNA variants thereof, gapmer variants thereof, and any combination or pooling thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the agent for suppressing expression of TGF-β2 is CGGCATGTCTATTTTGTA SEQ ID NO: 1 or C*G*G*C*A*T*G*T*C*T*A*T*T*T*T*G*T*A SEQ ID NO:137.

### Claim 9 (depends on 1)

The method of claim 1, The method, wherein the composition comprises a carrier of sterile water for injection, saline, isotonic saline, or a combination thereof.

### Claim 10 (depends on 1)

The method of claim 1, The method, wherein the composition is substantially free of excipients.

### Claim 11 (depends on 1)

The method of claim 1, The method, wherein the composition is stable for at least 14 days in carrier at 37° C.

### Claim 12 (depends on 1)

The method of claim 1, The method, wherein the immune checkpoint inhibitor is an inhibitor of PD-1, CTLA-4, or PD-L1.

### Claim 13 (depends on 1)

The method of claim 1, The method, wherein the immune checkpoint inhibitor is pembrolizumab, nivolumab, cemiplimab, spartalizumab, atezolizumab, avelumab, or durvalumab.

### Claim 14 (depends on 1)

The method of claim 1, wherein the interleukin immunotherapeutic active agent is a natural IL-2, a high dose IL-2, a recombinant IL-2, or aldesleukin.

### Claim 15 (depends on 1)

The method of claim 1, wherein the subject after all administrations has a reduced TGF-β2 expression.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The method of claim 1, wherein the subjects have an increased level of IRF5, an increased level of ITGAM, or a combination thereof.

### Claim 18 (depends on 1)

The method of claim 1, wherein the subjects have expression of ITGAM at a level above that found in a healthy patient.

### Claim 19 (depends on 1)

The method of claim 1, wherein the subjects after all administrations have an increased level of IRF5.

### Claim 20 (depends on 1)

The method of claim 1, wherein the subjects after all administrations have an increased level of ITGAM.

### Claim 21 (depends on 1)

The method of claim 1, comprising administering a therapeutically sufficient amount of a pharmaceutical composition comprising an expression product of IRF5 or ITGAM to the subject.

### Claim 22 (depends on 21)

The method of claim 21, wherein the expression product is an mRNA, a polypeptide, a protein, or fragment thereof, or combination thereof.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

The method of claim 1, wherein the method administration or use increases survival rate at month 6, 12, 18, 24, 30, or 36.

### Claim 25 (depends on 1)

The method of claim 1, wherein the method is combined with a standard of care treatment for cancer, wherein the standard of care treatment comprises chemotherapy or radiation therapy.
